The Biopharma A List: Taking The Pulse Of Newco Creation

The market for new company creation in the biopharma sector remains healthy and poised to continue fostering the establishment of start-ups, based on a new In Vivo study of the strong initial investments that pharma and biotech companies receive.

umbrella
• Source: Shutterstock

As the major introductory fundraise for start-ups, Series A financings represent the first-time companies raise substantial equity from venture investors. Prior to the Series A, new firms may raise funds from angel backers through seed rounds, but these are typically smaller in value.

Because Series As are a major milestone for companies just launching, they make an excellent proxy for new company formation,...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from VC Playbook

More from Growth

  • Arrowhead Moving Into Commercial Territory

     
    • By 

    Christopher Anzalone is spearheading Arrowhead Pharmaceuticals' transformation from a development-focused to a commercial-stage biotech. The CEO touts an “almost plug and play” platform, a derisked development strategy and a busy pipeline with vast potential.

  • 2023-2024 Global Biopharma R&D Productivity And Growth Ranking

     
    • By 

    The overall R&D productivity of the 30 largest public biopharma companies has increased despite a challenging global environment for investment and growth. Will hype cycles impact this picture in coming years?

  • podcast

    Podcast: Thermo Fisher’s Meron Mathias On Why Environmental Sustainability Must Be A Top Priority

     
    • By 

    Meron Mathias is vice president of CSR and sustainability at Thermo Fisher, whose specialty diagnostics division makes it the fifth leading player by revenues in the global IVD industry. In this podcast, she reflects on Thermo Fisher’s early commitment to ESG and sustainability reporting, its Scope 1, 2 and 3 targets and how regulation is moving industry towards a mandatory disclosure landscape.